Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys

Hepatology

Volumn 64, Issue 5, 2016, Pages 1430-1441

  Regan, Christopher P ^a   Morissette, Pierre ^a   Regan, Hillary K ^a   Travis, Jeffery J ^a   Gerenser, Pamela ^a   Wen, Jianzhong ^a   Fitzgerald, Kevin ^a   Gruver, Shaun ^a   DeGeorge, Joseph J ^a   Sannajust, Frederick J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DACLATASVIR; SOFOSBUVIR; UPRIFOSBUVIR; ANTIARRHYTHMIC AGENT; ANTIVIRUS AGENT; NUCLEOTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; GUINEA PIG MODEL; HEART ATRIOVENTRICULAR NODE; HEART ELECTROPHYSIOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; RHESUS MONKEY; SINUS NODE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; GUINEA PIG; HEART; HEPACIVIRUS; PHYSIOLOGY;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; GUINEA PIGS; HEART; HEPACIVIRUS; MACACA MULATTA; MALE; NUCLEOTIDES; SOFOSBUVIR;

EID: 84983372428     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28752     Document Type: Article

References (20)

1. French National Agency for Safety of Health Products and Medicines. Safety signal concerning the association of two antivirals, daclatasvir and/or sofosbuvir, in the treatment of chronic hepatitis C and/or amiodarone and the occurrence of cardiac arrhythmias. January 2015. Available at: http://ansm.sante.fr/S-informer/Travaux-de-l-Agence-Europeenne-des-Medicaments-EMA-Comite-pour-l-evaluation-des-risques-en-matiere-de-pharmacovigilance-PRAC/Finalisation-de-la-reevaluation-des-medicaments-contenant-de-l-ambroxol-ou-de-la-bromhexine-retour-d-information-sur-le-PRAC-de-janvier-2015-Point-d-information. Accessed on August 8, 2016.
2. European Medicines Agency. EMA recommends avoidance of certain hepatitis C medicines and amiodarone together. April 2015. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002313.jsp&mid=WC0b01ac058004d5c1. Accessed on August 8, 2016.
3. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another direct acting antiviral drug. March 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm. Accessed on August 8, 2016.
4. Amiodarone prescribing information. 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018972s038s039lbl.pdf. Accessed on August 8, 2016.
5. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including rechallenge. Gastroenterology 2015;149:1378–1380.
6. Fontaine H, Duboc D, Pol S. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med 2015;373:1886–1888.
7. Bateman KP, Cohen L, Emary B, Pucci V. Standardized workflows for increasing efficiency and productivity in discovery stage bioanalysis. Bioanalysis 2013;5:1783–1794.
8. Morissette P, Regan HK, Fitzgerald K, Bernasconi S, Gerenser P, Travis J, et al. QT interval correction assessment in the anesthetized guinea pig. J Pharmacol Toxicol Methods 2015;75:52–61.
9. Regan CP, Cresswell HK, Zhang R, Lynch JJ. Novel method to assess cardiac electrophysiology in the rat: characterization of standard ion channel blockers. J Cardiovasc Pharmacol 2005;46:68–75.
10. Regan HK, Lynch JJ, Regan CP. Long term assessment of blood pressure transducer drift in rhesus monkeys chronically instrumented with telemetry implants. J Pharmacol Toxicol Methods 2009;59:35–38.
11. Liu G, Tay CH, Rajamani S, Ray A, Stamm L, Vick J, et al. Effect of amiodarone and HCV direct-acting antiviral agents on cardiac conduction in nonclinical studies. In the 2016 International Liver Congress, April 13-17, Barcelona, Spain. Geneva, Switzerland: European Association for the Study of the Liver; 2016:FRI-162.
12. Daklinza prescribing information. 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843Orig1s000lbl.pdf. Accessed on August 8, 2016.
13. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015;149:1315–1317.
14. Chen Y, Mao J, Hop CE. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone. Drug Metab Dispos 2015;43:182–189.
15. Staubli M, Troendle A, Schmid B, Balmer P, Kohler B, Studer H, et al. Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. Eur J Clin Pharmacol 1985;29:417–423.
16. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 2015;54:677–690.
17. Choudhury M, Boyett MR, Morris GM. Biology of the sinus node and its disease. Arrhythm Electrophysiol Rev 2015;4:28–34.
18. Monfredi O, Maltsev VA, Lakatta EG. Modern concepts concerning the origin of the heartbeat. Physiology (Bethesda) 2013;28:74–92.
19. Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, et al. Identification of drug-drug interactions in vitro: a case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes. Toxicol Sci 2016, in press. doi: 10.1093/toxsci/kfw153.
20. Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, et al. Interaction between amiodarone and hepatitis C virus nucleoside inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK 293 cav1.2 over-expressing cells. Toxicol Appl Pharmacol, in press.